Skip to main content
. 2022 Mar 29;40(18):2023–2035. doi: 10.1200/JCO.21.01612

FIG 2.

FIG 2.

Outcomes for sorafenib-exposed versus -unexposed patients: (A-D) Overall and (E-H) by NPM1 status. (A) OS from study entry, (B) EFS from study entry, (C) DFS from CR, (D) RR from CR, (E) OS from study entry, (F) EFS from study entry by NPM1 status, (G) DFS from CR by NPM1 status, and (H) RR from CR by NPM1 status. CR, complete remission; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; RR, relapse risk; WT, wild-type.